BioCentury
ARTICLE | Clinical News

Xgeva regulatory update

February 1, 2017 9:43 PM UTC

Amgen withdrew an MAA from EMA for Xgeva denosumab seeking to expand the label to include treatment of hypercalcemia of malignancy refractory to IV bisphosphonate therapy. The company said it withdrew...